The UK and US have forged a key bilateral deal that will maintain no levies on UK pharmaceutical products being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the NHS. This move secures that duties on these vital products will be held at nothing for a period of 36 months.
This development comes after earlier statements to dramatically increase duties on patented pharmaceutical imports, with increases mentioned as high as double the cost.
"This deal with the Britain reinforces the global environment for innovative medicines and brings much-needed equity to American-British drug exports," a statement noted.
Trade Impact
Drugs are one of the the United Kingdom's most significant goods shipped to the US, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to the third quarter, the UK exported medicines totaling £11.1bn to the US. This figure represented a significant portion of total UK exports in that timeframe.
"This agreement secures jobs, stimulates funding and sets the stage for the UK to emerge as a international leader for life sciences," a government official commented.
Key British Pledges
The pact entails several notable pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to control costs will be restricted at 15%. In the past, rebates were more than 20%.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by assertions that American patients were paying a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while major expansions have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
